

1 **Original Article**

2 **Title**

3 Adherence to methotrexate and associated factors considering social desirability in patients
4 with rheumatoid arthritis: a multicenter cross-sectional study

5

6 **Authors**

7 Nobuyuki Yajima, MD, MPH, PhD^{1,2,3}; Takashi Kawaguchi, PhD⁴; Ryo Takahashi, MD¹;
8 Hiroki Nishiwaki, MD, MPH, PhD^{5,6}; Yoichi Toyoshima, MD, PhD (ORCID ID,
9 0000-0002-6097-2552)⁷; Koei Oh, MD, PhD⁸; Tsuyoshi Odai, MD, PhD^{9,10}; Takayuki Kanai,
10 MD, PhD¹¹; Donald E. Morisky, ScD, MSPH¹²; Takuhiro Yamaguchi, PhD¹³; Tsuyoshi
11 Kasama, MD, PhD (ORCID ID, 0000-0002-3871-6456)¹

12 **Affiliations**

13 ¹ Division of Rheumatology, Department of Medicine, Showa University School of Medicine,
14 Tokyo, Japan

15 ² Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine
16 and Public Health, Kyoto, Japan

17 ³ Center for Innovative Research for Communities and Clinical Excellence, Fukushima

18 Medical University, Fukushima, Japan

19 ⁴ Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy

20 and Life Sciences, Tokyo, Japan

21 ⁵ Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka

22 Hospital, Yokohama, Japan

23 ⁶ Showa University Research Administration Center, Tokyo, Japan

24 ⁷ Department of Orthopedic Surgery, Showa University Toyosu Hospital, Tokyo, Japan

25 ⁸ Department of Orthopedic Surgery, Showa University Northern Yokohama Hospital,

26 Yokohama, Japan

27 ⁹ Department of Internal Medicine, Showa University Northern Yokohama Hospital,

28 Yokohama, Japan

29 ¹⁰ Department of Rheumatology, Yokohama Asahi Central General Hospital, Kanagawa,

30 Japan.

31 ¹¹ Department of Nephrology, Kanto Rosai Hospital, Kawasaki, Japan

32 ¹² Department of Community Health Sciences, UCLA Fielding School of Public Health, Los

33 Angeles, United States

34 ¹³ Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan

35 **Corresponding author:**

36 Nobuyuki Yajima

37 Division of Rheumatology, Department of Medicine, Showa University School of Medicine,

38 Tokyo, Japan

39 Address:1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan

40 Phone: +81-3-3784-8942; Fax:+81-3-3784-8946

41 E-mail: n.yajima@med.showa-u.ac.jp

42 ORCID iD: 0000-0002-8292-3962

43

44 **Abstract**

45 **Background:** Assessing medication adherence in rheumatoid arthritis (RA) is clinically
46 significant as low adherence is associated with high disease activity. Self-reported medication
47 adherence surveys have been shown to have problems with overestimation of adherence due
48 to social desirability bias. However, no MTX adherence studies adjusted for social
49 desirability have been conducted to date. This study aimed to evaluate adherence to MTX and
50 perform an investigatory search for factors associated with MTX adherence including social
51 desirability.

52 **Methods:** This cross-sectional multicenter study was conducted among adult RA patients
53 consuming oral MTX for ≥ 3 months. We examined the distribution of MTX adherence,
54 according to the eight-item Morisky Medication Adherence Scale (MMAS-8). Social
55 desirability was using the Social Desirability Scale (SDS). Furthermore, an exploratory factor
56 analysis involving social desirability was examined to identify factors associated with MTX
57 adherence using linear regression analysis. To deal with missing values, we used multiple
58 imputations with chained equations methods.

59 **Results:** A total of 165 RA patients were enrolled. The median age was 64 years, and 86.1%
60 were women. Based on the MMAS-8, low, medium, and high adherences were noted in
61 12.1%, 60.0%, and 27.9% of participants, respectively. High social desirability (coefficient,
62 0.14; 95% confidence interval [CI], 0.05–0.23; $p < 0.05$) and high age (coefficient per 10 years,
63 0.16; 95% CI, 0.01–0.03; $p < 0.05$) were associated with high MTX adherence, whereas
64 full-time work was negatively associated with high MTX adherence (coefficient, -0.50; 95%
65 CI, -0.95–0.05; $p < 0.05$).

66 **Conclusions:** A large proportion of patients with RA do not take MTX as prescribed. High
67 social desirability, high educational level, and non-full-time work may be associated with
68 high MTX adherence. Physicians should confirm MTX adherence before switching or adding

69 disease-modifying anti-rheumatic drugs in cases of uncontrolled disease activity.

70 **Keywords:** rheumatoid arthritis, methotrexate, drug monitoring

71

72 **Background**

73 Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic
74 inflammation. RA affects the joints and leads to functional disability in the absence of
75 appropriate treatment [1]. The 2015 American College of Rheumatology (ACR) and the 2019
76 European League against Rheumatism recommendations suggested the early use of
77 disease-modifying antirheumatic-drugs (DMARDs), usually methotrexate (MTX), in most
78 active RA patients [2,3]. Several studies have reported that low medication adherence is
79 associated with high RA disease activity [4,5]. Hence, MTX adherence in RA patients is
80 crucial.

81 Non-adherence can be categorized as non-initiation, poor execution (accidental or
82 intentional) or non-persistence [6]. As a chronic disease, RA is important for drug
83 continuation, and attention should be focused on non-persistence non-adherence. Several
84 studies on adherence to MTX have been conducted. However, MTX adherence differed
85 among the studies because of the various definitions of adherence, different follow-up
86 durations, and heterogeneity of patient populations. A previous study reported that MTX

87 adherence is associated with age, sex, race, RA disease activity, patient beliefs about the
88 medication, disease duration, mental health, and socio-economic status (SES) [4,7-11]. In a
89 systematic review, beliefs on the necessity and efficacy of MTX, high mood, mild disease,
90 and MTX monotherapy were identified as the most reliable variables related to MTX
91 adherence [12].

92 The common propensity for people to show themselves in the most favorable light in
93 relation to society values and standards is known as social desirability [13]. Clinically, social
94 desirability may result in underreporting of socially and culturally "undesirable" habits and
95 behaviors, which may eventually result in lost chances for intervention and unrecognized
96 pharmacological contraindications [14,15]. It is well known to influence the use of
97 self-reported questionnaires in research. A previous study reported that social desirability is
98 the tendency to respond to self-reported items in a way that reflects better on the respondent
99 rather than acting accurately and truthfully [16]. Self-reported medication adherence surveys
100 have been shown to have problems with overestimation of adherence due to social
101 desirability bias [17,18]. A previous MTX adherence study has reported the need to control
102 this bias [19]; however, no studies have investigated the MTX adherence survey by
103 controlling for social desirability. Thus, this study aimed to evaluate the effect of already

104 known variables plus social desirability.

105 **Methods**

106 *Study design*

107 This cross-sectional study was conducted in four hospitals: Showa University Hospital,
108 Showa University Northern Yokohama Hospital, Showa University Fujigaoka Hospital, and
109 Kanto Rosai Hospital. Data collection was conducted only once during the survey.

110 *Patient population*

111 Participants were outpatients who met the 2010 ACR criteria for RA [20]. The inclusion
112 criteria were age ≥ 20 years and consumption of oral MTX for ≥ 3 months. The exclusion
113 criteria were patients with dementia, restlessness, and severe psychiatric disorders.
114 Consecutive sampling was employed. Patients were recruited between August 2013 and
115 October 2014.

116 *Outcome*

117 The primary outcome was the distribution of MTX adherence according to MMAS-8 at the
118 time of the survey based on the patient's description. MMAS-8 consists of an eight-item
119 questionnaire [21-23]. MMAS-8 scores range from 0 to 8 and are classified as follows: low,
120 < 6 ; medium, > 6 and < 8 ; and high, 8. Originally, MMAS-8 was developed for daily

121 administration of oral medicine. MTX was administered once a week; thus, we developed the
122 Japanese questionnaire for MTX accordingly after obtaining the original developer's
123 permission. First, a physician (N.Y.), a pharmacist (T.K.) with experience in scale
124 development translated the scale into Japanese. Second, it was back-translated into English
125 by two professional translators. N.Y., T.K. and two professional translators compared the
126 items with the original items, and discussed the questionnaire and achieved a consensus, and
127 revised the translated and back-translated versions. Finally, we were sent to the original
128 author to confirm the semantic content, and some minor improvements were made. The final
129 version was approved by the original author. Then, five Japanese RA participants took part in
130 a pilot test to see if they could understand the questions and respond to them clearly, if the
131 language was clear, if there were any technical or strange words that the subjects couldn't
132 understand, and if the questions were appropriate for Japanese culture.

133 ***Data collection***

134 Social desirability is typically assessed using the Social Desirability Scale (SDS) developed
135 by Crowne and Marlowe in 1960, with 33 items [24]. By "the urge to seek acceptance by
136 acting in a culturally relevant and acceptable way," this scale defines social desirability.
137 Furthermore, a 13-item SDS was developed with confirmed validity and reliability [25-27].

138 In this study, we used the 13-item SDS. The responses are recorded on “True” or “False. Add
139 1 point to the score for each “True” response to statements 5, 7, 9, 10, and 13. Add 0 points to
140 the score for each “False” response to these statements. Add 1 point to the score for each
141 “False” response to statements 1,2,3,4,6, 8, 11, and 12. Add 0 points to the score for each
142 “True” response to these statements. The score by domains ranges from 0 to 13. Higher
143 scores indicated higher social desirability.

144 MTX dose, MTX dosing frequency, duration of MTX treatment were collected. RA disease
145 activity was assessed using the Disease Activity Score in 28 joints (DAS28-ESR). [28].
146 Activities of daily living (ADL) was assessed using the modified Health Assessment
147 Questionnaire (mHAQ), which is a self-reported questionnaire that measures function,
148 including ADL performance. Depression state was defined using the Centre for
149 Epidemiological Studies-Depression (CES-D) scale-[29]. The patient’s perceptions towards
150 medications were assessed using the Belief about Medicines Questionnaire-Specific
151 (BMQ-specific), which includes two domains, BMQ-Specific necessity (5 items) and
152 BMQ-Specific concern (5 items). We used the BMQ necessity-concern differential
153 (“BMQ-Specific necessity” minus “BMQ-Specific concern”) predicted adherence most
154 strongly in studies affecting adherence [30]. Pain severity was assessed using the Brief Pain

155 Inventory (BPI).-We used the average numerical rating scale (NRS) pain score other clinical
156 studies have applied in the multivariable analysis. Short Form-8 (SF-8) is a health-related
157 quality of life (QoL) questionnaire [31,32]. We used two summary scores: mental component
158 summary (MCS; showing mental status) and physical component summary (PCS; showing
159 physical status). The Japanese versions of mHAQ, CES-D, BMQ, BPI, SDS, and SF-8 were
160 validated [33, 34].

161 Additionally, we obtained data on SES, including marital status, educational level,
162 employment status, and living status. Data on patient characteristics, medication, and SES
163 were further collected using questionnaires. Other data were obtained from medical chart
164 records. After consulting the doctor, the participants answered the Morisky Medication
165 Adherence Scale (MMAS-8), mHAQ, CES-D, BMQ, BPI, SDS, SF-8, and SES
166 questionnaires; they returned the completed questionnaires to the data center by mail.

167 *Statistical analyses*

168 MMAS-8, sex, CES-D, and SES were used as categorical variables, whereas age, MTX
169 dose, MTX dosing frequency, duration of MTX treatment, disease duration, DAS28-ESR,
170 mHAQ, BMQ, BPI, SDS, and SF-8 were used as continuous variables. Summary statistics
171 were presented as median with interquartile range (IQR) and numbers with proportion (%).

172 First, we evaluated the distribution of MTX adherence according to MMAS-8. Subsequently,
173 we compared MMAS-8 and pre-described factors using one-way analysis of variance
174 (ANOVA), Kruskal-Wallis test, and chi-squared test. For significant factors, we conducted a
175 trend analysis. Finally, multiple linear regression analysis was performed to exploratively
176 assess factors associated with MTX adherence. The co-variables selected were as follows: age,
177 sex, disease duration, RA disease activity (DAS28-ESR), depression state (CES-D),
178 reliability of the medication (BMQ necessity-concern differential), social desirability (SDS),
179 educational level (more than, equal to college-level, or not), and employment status (full-time
180 work or not). These factors were further selected based on previous studies and clinical
181 importance [4,7–11,35-37]. To compare the mean DAS-28 scores among the three groups
182 using ANOVA, the effect size (small, 0.1; medium, 0.25; and large: 0.4) customarily
183 proposed by Cohen [38] was set at medium (0.25), the significance level was set at 5% on
184 both sides, and the power was set at 80%. The total number of cases was calculated to be 159.
185 The target number of cases was 176, assuming a dropout rate of 10%.
186 To deal with missing values, we used multivariable multiple imputations with chained
187 equations methods to increase power and minimize selection bias since we considered
188 missing data to be an assumption of missing at random. We included age, sex, disease

189 duration, RA disease activity, depression state, reliability of the medication, social desirability,
190 educational level, and employment status for each imputation model. We generated 10
191 imputed datasets and combined coefficient estimates using Rubin's rules for each imputation.

192 A two-sided p-value <0.05 was considered statistically significant. All statistical analyses
193 were conducted using STATA 14.2 (StataCorp LP, College Station, TX) software.

194 ***Ethical considerations***

195 The ethics committee of Showa University Hospital (approval number 1446) and Showa
196 University Toyosu Hospital, Showa University Northern Yokohama Hospital, Kanto Rosai
197 Hospital approved this study, and informed consent was obtained from all participants before
198 study enrolment. All study procedures were performed in accordance with the Declaration of
199 Helsinki. Patient information was anonymized and de-identified before analysis.

200 **Results**

201 ***Patient flow chart***

202 Figure 1 shows the patient flow chart. Initially, 181 RA patients were invited. Of 169
203 patients eligible for the study, four were excluded because of missing MTX adherence data
204 (n=2) and clinical data (n=2). A total of 165 RA patients were included in the final analysis.

205 ***Baseline characteristics***

206 The characteristics of the participants are shown in Table 1. The median age of the patients
207 was 64 years (IQR, 54–72), and 86.1% were women. The median dose of MTX was 8 mg per
208 week (IQR, 6–12), median MTX dosing frequency was three times per week (IQR, 2–3), and
209 median duration of MTX treatment was 36 months (IQR, 17–75). The proportion of missing
210 data varied from 0 to 15.2% (Supplementary table 1).

211 **INSERT TABLE 1 HERE**

212 *Distribution of MTX adherence*

213 Based on MMAS-8, low, medium, and high adherence rates were noted in 12% (20/165),
214 60% (99/165), and 28% (46/165) of cases, respectively. The median MMAS-8 score was 7
215 (IQR, 6.5–8).

216 *Patient's characteristics by grade of MTX adherence*

217 Patient's characteristics by grade of MTX adherence divided by MMAS-8 are shown in
218 Table 1. A significant correlation between levels of MTX adherence and age, mHAQ, SDS,
219 SF-8 (PCS), and employment status was found. Based on trend analysis, older participants
220 had significantly high adherence, and the higher the social desirability, the higher the
221 adherence. However, a significant correlation between MTX adherence and mHAQ and SF-8
222 (PCS) was not observed in the trend analysis.

223 ***Factors associated with high MTX adherence considering social desirability***

224 In the multiple linear regression analysis adjusted for age, sex, disease duration, RA disease
225 activity (DAS28-ESR), depression state (CES-D), reliability of the medication (BMQ
226 necessity-concern differential), social desirability (SDS), educational level (more than or
227 equal to college-level or not), and employment status (full-time work or not), higher social
228 desirability (coefficient, 0.14; 95% confidence interval [CI], 0.05–0.23; $p<0.05$) and higher
229 age (coefficient per 10 years, 0.16; 95% CI, 0.01–0.03; $p<0.05$) were associated with high
230 MTX adherence, whereas full-time work was negatively related to high MTX adherence
231 (coefficient, -0.50; 95% CI, -0.95–0.05; $p<0.05$) (Table 2).

232 **INSERT TABLE 2 HERE**

233

234 **Discussion**

235 Elderly participants and high social desirability were significantly associated with high
236 adherence based on trend analysis. Multiple linear regression analysis showed that high MTX
237 adherence in RA patients is associated with high social desirability, high educational level,
238 and non-full-time work.

239 In our study, only 27.9% of the participants showed high medication adherence. Several

240 studies reported that adherence to DMARDS was 40%–107% [10,39,40]. There are several
241 potential reasons for the observed low adherence. First, the method of adherence
242 measurement in each study was different. There were interviews, questionnaires, tablet count,
243 drug concentration, and doctor’s judgment as measurements. A previous study showed that
244 the adherence to interview, tablet count, drug concentration, and doctor’s judgment were 96%,
245 77%, 58%, and 42%, respectively, which showed vast differences [41]. Since each
246 measurement has advantages and disadvantages, the gold standard is not determined. We
247 chose a self-reported questionnaire in this study since this scale is not expensive or invasive
248 and can be possibly validated. Second, the time point of adherence measurement was
249 different between the studies. We measured adherence during the maintenance period (mean
250 disease duration, 53 months). A previous report suggested that the adherence of DMARDs in
251 the early period was low (58%) [5]. Another study reported the adherence to
252 salazosulfapyridine as 87% at three years from the start of medication [36]. In contrast, the
253 adherence to DMARDs in the maintenance period varied from 84%,⁴ 70% [42], to 95.4%
254 [43]. Previous reports have suggested that the adherence to DMARDs was not different
255 between the early and maintenance periods. It is crucial to note that the time point of
256 measuring medication adherence is the maintenance period because RA is a chronic disease

257 that requires DMARDs for a long duration. The third is the difference in participant
258 characteristics. Living status and marital status affected adherence [11, 44]. Our study could
259 not adjust the living status and marital status because we could not include more factors
260 based on our sample size. In addition, the age of the participants may have had an effect. In
261 the original MMAS-8 article [21], the mean age was 52 years; however, in our study, the
262 median age was 64 years, which means that the participants in our study were older, and this
263 may have influenced the results. Furthermore, older people may not have revealed the truth.
264 Thus, when referring to drug adherence studies, the method of measuring adherence, whether
265 the target patient is in the disease's early or maintenance phase, and the patient's
266 characteristics should be confirmed before adaptation.

267 Our study detected high social desirability, high educational level, and non-full-time work
268 as factors affecting MTX adherence. A previous study reporting MTX adherence found that
269 adherence is associated with age, sex, race, RA disease activity, patient beliefs about the
270 medication, disease duration, mental health, and SES [4,7-11,35-37]. The discrepancy
271 between our findings and those of other studies could be attributed to three reasons. First, we
272 measured and adjusted social desirability, which possibly affected the answers in the
273 questionnaire. Although a recent MTX adherence research mentioned the necessity to

274 account for this bias [19], no studies have examined how MTX adherence survey accounts
275 for social desirability. The results may have differed since we conducted a factor search that
276 included social desirability. Second, racial differences may have led to different outcomes.
277 Our study was based on a Japanese population; however, previous studies were mainly on
278 white people, black people, and Hispanic people. Canon et al. reported that the adherence to
279 MTX was associated with the Caucasian race [4]. Therefore, adherence may be influenced by
280 race. Third, the definition of medication adherence varies between studies. We used MMAS-8
281 in our study. Conversely, previous studies used other methods to assess medication adherence,
282 such as physicians' estimation, different self-reported scales, drug concentration, tablet count
283 electronic monitors, and other questionnaires. A prior study reported that medication
284 adherence differs because the measurement method employed seems to vary [12]. Therefore,
285 we need to practice caution when using research results because the results may differ
286 depending on the method of measuring adherence and the variables incorporated, including
287 social desirability.

288 Our study had three strengths. First, we assessed social desirability, leading to social
289 desirability bias. To our knowledge, no clinical studies adjusting social desirability have
290 investigated the association between MTX adherence and various factors. Second, to our

291 knowledge, this is the first research to examine MTX adherence in an Asian population. Third,
292 the response rate to the questionnaires was high (93.4%), thereby strengthening internal
293 validity.

294 This study has significant implications for the clinician. Our findings may prevent
295 unnecessary DMARDs changes since physicians tend to overestimate patients' medication
296 adherence [45]. They should confirm MTX adherence before switching or adding DMARDS.
297 Accordingly, this provides an opportunity to reduce the healthcare cost and adverse events of
298 medication.

299 However, this study had several limitations. First, in the multivariable analysis, some
300 immeasurable essential factors (such as characteristics of each participant, joint deformities,
301 number of medications, and MTX dosing frequency) that could affect MTX adherence
302 possibly exist. We did not determine patient personality due to the difficulty in quantifying it.

303 In addition, we did not collect radiographs even if they are necessary for determining joint
304 deformity because they are burdensome for patients. However, we adjusted for joint
305 deformity using the mHAQ to reduce its possible influence on the findings. In addition,
306 although the number of MTX doses was collected, it was not possible to incorporate variables
307 due to sample size limitations. Second, the generalizability of our findings is limited. Our

308 study setting was primarily university hospitals in Japan; thus, the results of this study cannot
309 be applied to the clinical setting, in small- and medium-sized hospitals, or in settings
310 including other races. Furthermore, the highest dose of MTX in Japan in the study was 8 mg
311 per week. This dose is less than the standard dose of 20 mg worldwide, which limits the
312 indications. Third, we used a self-reported questionnaire of adherence. Hence, the completed
313 questionnaire possibly influenced social desirability. Although we could not adjust this bias
314 completely, social desirability was added as a factor for analysis. Furthermore, MMAS-8 is
315 "self-perceived adherence" and not true drug adherence. Therefore, even a factorial search
316 including social desirability may not reveal the truth. Forth, The Marlowe-Crowne Social
317 Desirability scale may have inadequate validity and reliability [46]. The validity of this scale
318 has not been examined in the target population of RA patients. There are also negative studies
319 on the reliability of the SDS scale. As a future study, we would like to conduct a validity
320 study of this scale in RA patients.

321 **Conclusions**

322 Our results demonstrated that sixty percent of the RA patients had moderate adherence to
323 MTX. Moreover, high MTX adherence in RA patients is associated with high social
324 desirability, high educational level, and non-full-time work.

325

326 **List of Abbreviations**

327 ADL: Activities of Daily Living

328 BMQ: Beliefs about Medicines Questionnaire

329 BPI: Brief Pain Inventory

330 CES-D: Center for Epidemiological Studies Depression

331 DAS28-ESR: Disease Activity Score (28 joint count)-erythrocyte sedimentation rate

332 DMARDs: disease-modifying antirheumatic-drugs

333 MCS: mental component summary

334 mHAQ: modified Health Assessment Questionnaire

335 MMAS-8: Morisky Medication Adherence Scale

336 MTX: methotrexate

337 NRS: Numerical Rating Scale

338 PCS: physical component summary

339 RA: rheumatoid arthritis

340 SDS: Social Desirability Scale

341 SF-8: 8-item Short-Form Health Survey

342

343 **Declarations**

344 *Ethics approval and consent to participate*

345 The ethics committee of Showa University Hospital (approval number 1446) and other each
346 institution approved this study, and informed consent was obtained from all participants
347 before study enrolment. All study procedures were performed in accordance with the
348 Declaration of Helsinki. Patient information was anonymized and de-identified before
349 analysis.

350 *Consent for publication*

351 Not applicable.

352 *Availability of data and materials*

353 The dataset analyzed in this paper is available from the corresponding author on reasonable
354 request.

355

356 **About MMAS8**

357 The use of the MMAS diagnostic adherence assessment instrument is protected by US
358 copyrighted and trademarked laws. Permission for use is required. A license is available from

359 MORISKY MEDICATION ADHERENCE RESEARCH, LLC., Donald E. Morisky, ScD,
360 ScM, MSPH, MMAR, LLC, 294 Lindura Ct., Las Vegas, NV 89138; dmorisky@gmail.com.

361

362 ***Competing interests***

363 Donald E. Morisky holds a copyright for the Morisky Medication Adherence Scale-8, is one
364 of its authors, and collects fees in exchange for licenses to use the scale in research. This does
365 not alter the authors' commitment to objectivity in research or adherence to data sharing
366 policies. He was not involved in any data analysis. For the remaining authors, none were
367 declared.

368 ***Funding***

369 The authors have not received funding to conduct this study.

370 ***Authors' contributions***

371 Nobuyuki Yajima: Methodology, Project administration, Writing – original draft, Writing –
372 Review & Editing

373 Takashi Kawaguchi: Supervision, Conceptualization, Project Administration, Writing –
374 original draft, Writing – Review & Editing

375 Ryo Takahashi: Data curation, Writing – original draft, Writing – Review & Editing

- 376 Hiroki Nishiwaki: Data curation, Writing – original draft, Writing – Review & Editing
- 377 Youichi Toyoshima: Data curation, Writing – original draft, Writing – Review & Editing
- 378 Koei O: Data curation, Writing – original draft, Writing – Review & Editing
- 379 Tsuyoshi Odai: Data curation, Writing – original draft, Writing – Review & Editing
- 380 Takayuki Kanai: Data curation, Writing – original draft, Writing – Review & Editing
- 381 Donald E. Morisky: Supervision, Writing – original draft, Writing – Review & Editing
- 382 Takuhiro Yamaguchi: Formal Analysis, Supervision, Writing – original draft, Writing –
- 383 Review & Editing
- 384 Tsuyoshi Kasama: Supervision, Writing – original draft, Writing – Review & Editing
- 385 ***Acknowledgments***
- 386 We thank Noboru Murata (Kikuna Memorial Hospital) and Osamu Namiki for critically
- 387 reviewing the manuscript.
- 388
- 389 ***Authors' information***
- 390 **Division of Rheumatology, Department of Medicine, Showa University School of**
- 391 **Medicine, Tokyo, Japan**
- 392 Nobuyuki Yajima, Ryo Takahashi, Tsuyoshi Kasama

393 **Department of Healthcare Epidemiology, Kyoto University Graduate School of**

394 **Medicine and Public Health, Kyoto, Japan**

395 Nobuyuki Yajima

396 **Center for Innovative Research for Communities and Clinical Excellence, Fukushima**

397 **Medical University, Fukushima, Japan**

398 Nobuyuki Yajima

399 **Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy**

400 **and Life Sciences, Tokyo, Japan**

401 Takashi Kawaguchi

402 **Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka**

403 **Hospital, Yokohama, Japan**

404 Hiroki Nishiwaki

405 **Showa University Research Administration Center, Tokyo, Japan**

406 Hiroki Nishiwaki

407 **Department of Orthopedic Surgery, Showa University Toyosu Hospital, Tokyo, Japan**

408 Yoichi Toyoshima

409 **Department of Orthopedic Surgery, Showa University Northern Yokohama Hospital,**

410 **Yokohama, Japan**

411 Koei Oh

412 **Department of Internal Medicine, Showa University Northern Yokohama Hospital,**

413 **Yokohama, Japan**

414 Tsuyoshi Odai

415 **Department of Rheumatology, Yokohama Asahi Central General Hospital, Kanagawa,**

416 **Japan.**

417 Tsuyoshi Odai

418 **Department of Nephrology, Kanto Rosai Hospital, Kawasaki, Japan**

419 Takayuki Kanai

420 **Department of Community Health Sciences, UCLA Fielding School of Public Health**

421 Donald E. Morisky

422 **Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi,**

423 **Japan**

424 Takuhiro Yamaguchi

425

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

426

427

428

429

430

431

432

433

434

435

436

437 **References**

- 438 1. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van
439 Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year
440 prospective followup of patients with early rheumatoid arthritis. *Arthritis Rheum.*
441 1992;35:26-34.
- 442 2. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015
443 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis.
444 *Arthritis Care Res (Hoboken)*. 2016;68:1-25.
- 445 3. Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M,
446 Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid
447 arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
448 *Ann Rheum Dis*. 2020;79:685-99.
- 449 4. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al.
450 Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess
451 methotrexate adherence and disease activity in clinical practice. *Arthritis Care Res*
452 (Hoboken). 2011;63:1680-90.
- 453 5. Contreras-Yanez I, Ponce De Leon S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V.

454 Inadequate therapy behavior is associated to disease flares in patients with rheumatoid
455 arthritis who have achieved remission with disease-modifying antirheumatic drugs. *Am J*
456 *Med Sci.* 2010;340:282-90.

457 6. Brodtkorb E, Samsonsen C, Sund JK, Bråthen G, Helde G, Reimers A. Treatment
458 non-adherence in pseudo-refractory epilepsy. *Epilepsy Res.* 2016;122:1-6

459 7. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants of
460 methotrexate adherence in rheumatoid arthritis patients. *Clin Rheumatol.* 2016;35:1335-9.

461 8. DiBenedetti DB, Zhou X, Reynolds M, Ogale S, Best JH. Assessing methotrexate
462 adherence in rheumatoid arthritis: a cross-sectional survey. *Rheumatol Ther.* 2015;2:73-84.

463 9. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in patients
464 with rheumatoid arthritis: a narrative review of the literature. *Orthop Nurs.* 2010;29:260-75.

465 10. Scheiman-Elazary A, Duan L, Shourt C, Shourt C, Agrawal H, Ellashof D, et al. The
466 rate of adherence to antiarthritis medications and associated factors among patients with
467 rheumatoid arthritis: a systematic literature review and metaanalysis. *J Rheumatol.*
468 2016;43:512-23.

469 11. Waimann CA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A, Reveille JD,
470 et al. Electronic monitoring of oral therapies in ethnically diverse and economically

- 471 disadvantaged patients with rheumatoid arthritis: consequences of low adherence. *Arthritis*
472 *Rheum.* 2013;65:1421-9.
- 473 12. Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM.
474 Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings
475 from a systematic review of rates, predictors and associations with patient-reported and
476 clinical outcomes. *RMD Open.* 2016;2:e000171.
- 477 13. Tracey, Terence J G. A note on socially desirable responding. *Journal of counseling*
478 *psychology.* 2016;63:224-32.
- 479 14. Copeland K, Checkoway H, McMichael A. and Holbrook R. Bias due to the
480 misclassification in the estimation of relative risk. *Am J Epidemiology.* 1977;105:488–95.
- 481 15. Richman WL, Weisband S, Kiesler S. and Drasgow F. A meta-analytic study of
482 social desirability distortion in computer-administered questionnaires, traditional
483 questionnaires, and interviews. *Journal of Applied Psychology.* 1999;84: 754–775
- 484 16. Holtgraves T. Social desirability and self-reports: testing models of socially desirable
485 responding. *Pers Soc Psychol Bull.* 2004;30:161-72.
- 486 17. Hebel S, Kahn-Woods E, Malone-Thomas S, McNeese M, Thornton L,
487 Sukhija-Cohen A, et al. Brief report: discrepancies between self-reported adherence and a

- 488 biomarker of adherence in real-world settings. *J Acquir Immune Defic Syndr.*
489 2020;85:454-7.
- 490 18. van der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological lessons
491 from clinical trials and the future of microbicide research. *Curr HIV/AIDS Rep.*
492 2013;10:89-102.
- 493 19. Aaltonen KJ, Turunen JH, Sokka T, Puolakka K, Valleala H. A survey on the
494 medication adherence to methotrexate among rheumatoid arthritis patients treated with
495 self-administered biologic drugs. *Clin Exp Rheumatol.* 2016;34:694-7.
- 496 20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010
497 rheumatoid arthritis classification criteria: an American College of Rheumatology/European
498 League against Rheumatism collaborative initiative. *Arthritis Rheum.* 2010;62:2569-81.
- 499 21. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication
500 adherence measure in an outpatient setting. *J Clin Hypertens. (Greenwich)* 2008;10:348-54.
- 501 22. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, et al. Effect
502 of intensive blood-pressure treatment on patient-reported outcomes. *N Engl J Med.*
503 2017;377:733-44.
- 504 23. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, et al.

- 505 Cost-effectiveness of intensive versus standard blood pressure control. *N Engl J Med.*
- 506 2017;377:745-55.
- 507 24. Crowne DP, Marlowe D. A new scale of social desirability independent of
- 508 psychopathology. *J Consult Psychol.* 1960;24:349-54.
- 509 25. Reynolds WM. Development of reliable and valid short forms of the
- 510 Marlowe-Crowne social desirability scale. *J Clin Psych.* 1982;38:119-25.
- 511 26. Barger, S. D. The Marlowe-Crowne affair: Short forms, psychometric structure, and
- 512 social desirability. *Journal of Personality Assessment.* 2003;79:286-305.
- 513 27. Nederhof, A. J. Methods of coping with social desirability bias: A review. *European*
- 514 *Journal of Social Psychology.* 1985;15:263-280.
- 515 28. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van
- 516 Riel PL. Modified disease activity scores that include twenty-eight-joint counts.
- 517 Development and validation in a prospective longitudinal study of patients with rheumatoid
- 518 arthritis. *Arthritis Rheum.* 1995;38:44-8.
- 519 29. Radloff LS. The CES-D scale: a self-report depression scale for research in the
- 520 general population. *Appl Psychol Meas.* 1977;1:385-401.
- 521 30. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in

- 522 adherence to treatment in chronic physical illness. *J Psychosom Res.* 1999;47:555-67.
- 523 31. Ware JE, GlaxoSmithKline. How to score and interpret single-item health status
524 measures: a manual for users of the of the SF-8 health survey: (with a supplement on the
525 SF-8 health survey). Lincoln, RI; QualityMetric, Inc.; Boston, MA: Health Assessment Lab.
526 2001.
- 527 32. Birrell FN, Hassell AB, Jones PW, Dawes PT. How does the short form 36 health
528 questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and
529 SF-36 population values? A cross-sectional study. *Clin Rheumatol.* 2000;19:195-9.
- 530 33. Iihara N, Suzuki K, Kurosaki Y, Morita S, Hori K. Factorial invariance of a
531 questionnaire assessing medication beliefs in Japanese non-adherent groups. *Pharm World*
532 *Sci.* 2010;32:432-9.
- 533 34. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain
534 assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory--BPI-J. *J Pain*
535 *Symptom Manage.* 1998;16:364-73.
- 536 35. Lorish CD, Richards B, Brown S. Missed medication doses in rheumatic arthritis
537 patients: intentional and unintentional reasons. *Arthritis Care Res.* 1989;2:3-9.
- 538 36. Brus HL, van de Laar MA, Taal E, Rasker JJ, Wiegman O. Effects of patient

- 539 education on compliance with basic treatment regimens and health in recent onset active
540 rheumatoid arthritis. *Ann Rheum Dis*. 1998;57:146-51.
- 541 37. Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W.
542 Compliance with drug therapy in rheumatoid arthritis. A longitudinal European study. *Joint
543 Bone Spine*. 2000;67:178-82.
- 544 38. Cohen, J. A power primer. *Psychol Bull*. 1992;112:155-9.
- 545 39. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients
546 with rheumatoid arthritis: a critical appraisal of the existing literature. *Expert Rev Clin
547 Immunol*. 2012;8:337-51.
- 548 40. Curtis JR, Bykerk VP, Aassi M, Schiff M. Adherence and persistence with
549 methotrexate in rheumatoid arthritis: a systematic review. *J Rheumatol*. 2016;43:1997-2009.
- 550
- 551 41. Pullar T, Peaker S, Martin MF, Bird HA, Feely MP. The use of a pharmacological
552 indicator to investigate compliance in patients with a poor response to antirheumatic therapy.
553 *Br J Rheumatol*. 1988;27:381-4.
- 554 42. van den Bemt BJ, den Broeder AA, van den Hoogen FH, Benraad B, Hekster YA,
555 van Riel PL, et al. Making the rheumatologist aware of patients' non-adherence does not

- 556 improve medication adherence in patients with rheumatoid arthritis. *Scand J Rheumatol.*
- 557 2011;40:192-6.
- 558 43. Park DC, Hertzog C, Leventhal H, Morrell RW, Leventhal E, Birchmore D, et al.
- 559 Medication adherence in rheumatoid arthritis patients: older is wiser. *J Am Geriatr Soc.*
- 560 1999;47:172-83.
- 561 44. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants of
- 562 methotrexate adherence in rheumatoid arthritis patients. *Clin Rheumatol.* 2016;35:1335-9.
- 563 45. Gossec L, Molto A, Romand X, Puyraimond-Zemmour D, Lavielle M, Beauvais C,
- 564 et al. Recommendations for the assessment and optimization of adherence to
- 565 disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on
- 566 literature reviews and expert consensus. *Joint Bone Spine.* 2019;86:13-19
- 567 46. Nurumov K, Hernández-Torrano D, Ait Si Mhamed A, Ospanova U. Measuring
- 568 Social Desirability in Collectivist Countries: A Psychometric Study in a Representative
- 569 Sample From Kazakhstan. *Front Psychol.* 2022;13:822931.

570

571 **Figure Legend**

572 **Figure 1.** Patient flow chart

573

574 **Tables**

575 **Table 1. Patient characteristics by grade of MTX adherence divided by MMAS-8 (n=165)**

576

	All (n=165)	MMAS-8			P value
		Low (n=20)	Medium (n=99)	High (n=46)	
Age, median (IQR)	64 (54–72)	58 (44–62)	65 (53–73)	65.5 (59–74)	0.01
Female, n (%)	142 (86.1)	18 (90.0)	84 (84.6)	38 (82.6)	0.74
MTX dose (mg/week), median (IQR)	8 (6–12)	10 (8–12)	8 (6–10)	10 (8–12)	0.17
MTX dosing frequency (times/week), median (IQR)	3 (2–3)	3 (2–3)	2 (2–3)	2 (2–3)	0.54
Duration of MTX treatment (month), median (IQR)	36 (17–75)	32 (16–79)	35 (18–80)	41 (13–74)	0.15
Disease duration (month), median (IQR)	53.5 (22.5–123.5)	35 (22–120)	47 (22–111)	60.5 (24–158)	0.95
Concomitant medication					
NSAIDs, n (%)	59 (35.8)	5 (25.0)	36 (36.4)	8 (39.1)	0.53
Corticosteroid, n (%)	27 (16.4)	2 (10.0)	17 (17.2)	8 (17.4)	0.71
Biologics, n (%)	48 (29.1)	7 (35.0)	28 (28.3)	13 (28.3)	0.83
DAS28-ESR, median (IQR)	2.30 (1.68–3.00)	2.01 (1.37–2.23)	2.32 (1.68–3.02)	2.40 (2.01–3.15)	0.08
mHAQ, median (IQR)	0 (0–0.13)	0 (0–0.25)	0 (0–0)	0.13 (0–0.38)	0.02
BMQ necessity-concern differential, median (IQR)	1 (0–3)	2 (0–3)	1 (0–3)	2 (0–3)	0.81
CES-D (total score ≥ 16), n	37 (26.4)	8 (47.1)	21 (8.3)	8 (20.0)	0.10

(%)					
BPI (average NRS pain score), median (IQR)	2 (1–3)	1 (1–4)	1 (1–3)	1 (3–4)	0.13
SDS, median (IQR)	6 (4–7)	4 (3–6)	6 (4–6)	6.5 (5–8)	0.00
SF-8 (PCS), median (IQR)	48.1 (42.4–52.1)	47.4 (45.8–52.1)	49.8 (43.5–52.1)	45.6 (40.2–50.2)	0.04
SF-8 (MCS), median (IQR)	50.2 (45.6–54.1)	47.7 (43.0–53.2)	50.3 (46.3–53.9)	50.0 (46.1–55.0)	0.36
Marital status (married), n (%)	95 (57.9)	11 (55.0)	61 (62.2)	23 (50.0)	0.37
Educational level (greater than or equal to college level), n (%)	36 (21.8)	5 (25.0)	17 (17.2)	14 (30.4)	0.19
Employment status (full-time), n (%)	38 (23.0)	12 (60.0)	22 (22.2)	4 (8.7)	0.00
Living status (living alone), n (%)	43 (26.4)	7 (35.0)	24 (24.5)	12 (26.7)	0.62

577 IQR, interquartile range; DAS28-ESR, Disease Activity Score (28 joint count)- erythrocyte sedimentation
 578 rate; mHAQ, modified Health Assessment Questionnaire; BMQ, Beliefs about Medicines Questionnaire;
 579 CES-D, Center for Epidemiological Studies Depression; BPI, Brief Pain Inventory; NRS, Numerical
 580 Rating Scale; SDS, Social Desirability Scale; SF-8, 8-item Short-Form Health Survey; PCS, physical
 581 component summary; MCS, mental component summary; MTX, methotrexate; MMAS-8, Morisky
 582 Medication Adherence Scale

583

584 **Table 2. Factors associated with MTX adherence using linear regression analysis (n=165)**

	Coef.	95% CI	p value
Age	0.02	0.00–0.03	0.03

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Female	-0.09	-0.58–0.40	0.73
Disease duration	0.00	-0.00–0.00	0.41
RA activity (DAS28-ESR)	0.16	-0.03–0.35	0.09
Depression state (CES-D)	-0.26	-0.69–0.18	0.25
Belief about medicine (BMQ necessity-concern differential)	0.01	-0.07–0.09	0.86
Social desirability (SDS)	0.14	0.05–0.23	0.00
Educational level (more than or equal to college level or not)	0.36	-0.10–0.82	0.13
Employment status (full-time work or not)	-0.50	-0.95–-0.05	0.03

585

586 * Linear regression analysis was used to detect factors associated with MTX adherence

587 * MTX, methotrexate; RA, rheumatoid arthritis; DAS28-ESR, Disease Activity Score (28 joint

588 count)-erythrocyte sedimentation rate; BMQ, Beliefs about Medicines Questionnaire; CES-D, Center for

589 Epidemiological Studies Depression; SDS, Social Desirability Scale; Coef, regression coefficients; CI,

590 confidence interval

591

Figure 1. Patient flow chart

